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Obesity is associatedwith a chronic state of low-grade inflammation
and progressive tissue infiltration by immune cells and increased
expression of inflammatory cytokines. It is established that inter-
leukin 6 (IL6) regulates multiple aspects of metabolism, including
glucose disposal, lipolysis, oxidative metabolism, and energy expen-
diture. IL6 is secreted by many tissues, but the role of individual cell
types is unclear. We tested the role of specific cells using a mouse
model with conditional expression of the Il6 gene.We found that IL6
derived from adipocytes increased, while IL6 derived from myeloid
cells and muscle suppressed, macrophage infiltration of adipose tis-
sue. These opposite actions were associated with a switch of IL6
signaling from a canonical mode (myeloid cells) to a noncanonical
trans-signaling mode (adipocytes and muscle) with increased ex-
pression of the ADAM10/17 metalloprotease that promotes trans-
signaling by the soluble IL6 receptor α. Collectively, these data
demonstrate that the source of IL6 production plays a major role
in the physiological regulation of metabolism.
adipose tissue | inflammation | interleukin 6 | insulin resistance
Interleukin 6 (IL6) is a cytokine with many physiological actionsthat regulate metabolism (1). Indeed, studies using IL6 infusion
in healthy humans demonstrate increased insulin-stimulated glu-
cose disposal, increased lipolysis, increased glucose and fatty acid
oxidation, and increased energy expenditure (2, 3). IL6 therefore
targets multiple physiological processes that impact whole-body
metabolism. The physiology of IL6 signaling is complex because
the effects of IL6 on metabolism requires signal integration between
cell types (4) that involve proinflammatory, anti-inflammatory, and
noninflammatory mechanisms (5).
The molecular mechanism of IL6 signaling is mediated by IL6
receptor α (IL6-Rα) through the signaling protein IL6ST (also
known as gp130). Canonical IL6 signaling involves binding of
IL6 to an IL6-Rα/IL6ST complex at the plasma membrane (5).
Noncanonical (trans) IL6 signaling is mediated by the interaction
of IL6ST with a proteolytically processed (soluble) form of IL6-Rα
bound to IL6 (5). Both forms of IL6 signaling lead to activation of
the JAK1–STAT3 pathway (5). Targets of IL6-stimulated STAT3
signaling include the Il4ra promoter that leads to increased IL4-Rα
expression by macrophages that promotes alternative (M2a) acti-
vation and suppression of obesity-induced insulin resistance (6).
Similarly, IL6 signaling by hepatocytes causes increased tolerance
to both glucose and insulin (7). Moreover, IL6 acts on adipose
tissue to increase leptin secretion and suppress satiety (8), and IL6
increases adipose tissue lipolysis (8), which, in turn, promotes
hepatic gluconeogenesis (9) and hepatic insulin resistance (9, 10).
IL6 also increases the loss of adipose tissue following exercise (11)
and in response to cancer cachexia (12). Furthermore, IL6 sig-
naling in the paraventricular nucleus of the hypothalamus im-
proves energy and glucose homeostasis in response to obesity (13).
It has also established that IL6 can increase insulin secretion by an
incretin-based mechanism (14). IL6 is therefore a potent cytokine
that acts at key sites of metabolic regulation in multiple tissues.
Indeed, tissue-specific knockout mice confirm that IL6 plays an
important role in the obesity response (15–23).
While insight concerning the complex actions of IL6 on me-
tabolism has been obtained, the consequences of IL6 production
by specific tissues is poorly understood because the source of IL6
under many physiological conditions has not been established. It
is known that adipose tissue represents a major source of increased
circulating IL6 caused by obesity (24, 25), but the relevant adipose-
tissue cell type is unclear because Il6 messenger RNA (mRNA) is
expressed by adipocytes, adipose tissue macrophages (ATMs), and
other adipose-tissue cell types (1). Here, we tested the relative
roles of IL6 expression by ATMs and adipocytes by comparing
mice with Il6 gene ablation selectively in adipocytes or myeloid
cells. We found that adipocyte IL6 potently promotes ATM ac-
cumulation in the absence of major changes in glucose or insulin
tolerance. In contrast, myeloid cell IL6 suppresses M1 macrophage
polarization, reduces ATM accumulation, and improves tolerance
to both glucose and insulin. These data demonstrate that the
source of IL6 dramatically affects the physiological metabolic re-
sponse to IL6 in vivo.
Results
Adipose Tissue Inflammation Associated with Diet-Induced Obesity.
C57BL/6J male mice were fed a chow diet (CD) or a high-fat diet
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(HFD), and gonadal white adipose tissue (gWAT) macrophages
(ATMs) were examined by flow cytometry. The number of F4/80+
ATMs was dramatically increased by feeding a HFD (Fig. 1A
and SI Appendix, Fig. S1 A and B). Immunophenotyping dem-
onstrated increased numbers of both F4/80+ CD11c+ CD206−
ATM (M1-like) and F4/80+ CD11c− CD206+ ATM (M2-like)
macrophages (Fig. 1B and SI Appendix, Fig. S1C). Gene-expression
analysis demonstrated selective expression of Adipoq mRNA by
the adipocyte fraction (ADF) and Adgre1 mRNA by the stromal
vascular fraction (SVF) (Fig. 1C). Inflammatory gene expression
was increased in both the ADF and SVF when mice were fed a
HFD, including Ccl2, Ccl5, Il6, and Tnfα (Fig. 1C). The source of
inflammatory cytokine/chemokine expression in the adipose tis-
sue of HFD-fed mice is therefore unclear.
Further studies of inflammatory cytokine expression in adipose
tissue were focused on IL6. Both adipocytes and macrophages
represent potential sources of adipose tissue IL6. We therefore
examined Il6mRNA expression in control mice and mice with IL6
deficiency in adipocytes (Adipoq-Cre+/− Il6LoxP/LoxP) or myeloid
cells (Lyz2-Cre+/− Il6LoxP/LoxP) (SI Appendix, Fig. S1 D and E). We
found that the HFD-induced expression of Il6 mRNA in adipose
tissue was suppressed by IL6 deficiency in either adipocytes or
myeloid cells (Fig. 1 D and E). Moreover, the serum concentration
of IL6 was reduced by IL6 deficiency in either adipocytes or my-
eloid cells (SI Appendix, Fig. S1 F andG). These data indicate that
IL6 may be secreted by both adipocytes and macrophages in the
adipose tissue of HFD-fed mice. However, the relative role of IL6
expression by these cell types is unclear.
Adipocyte IL6 Promotes HFD-Induced Adipose Tissue Inflammation.
To examine the role of IL6 secreted by adipocytes, we compared
control ADWT mice (Adipoq-Cre+/−) and mice with IL6-deficiency
(ADΔIL6) in adipocytes (Adipoq-Cre+/− Il6LoxP/LoxP). No differ-
ences in body mass were detected in mice fed a CD or a HFD
(Fig. 2 A and B). Metabolic cage analysis demonstrated that
adipocyte IL6 deficiency in HFD-fed mice caused increased
energy expenditure (SI Appendix, Fig. S2 A and B), increased
food consumption (SI Appendix, Fig. S2C), increased core body
temperature (SI Appendix, Fig. S2D), and reduced triglyceride
accumulation by the liver and brown adipose tissue (BAT) (SI
Appendix, Fig. S2 F–H) compared with HFD-fed control mice.
The absence of a weight-gain difference between HFD-fed
control and HFD-fed adipocyte IL6-deficient mice most likely
represents a compound phenotype that balances increased food
consumption with increased energy expenditure.
Analysis of the circulating concentration of hormones dem-
onstrated that adipocyte IL6 deficiency caused no changes in
HFD-induced hyperinsulinemia or hyperleptinemia, although a
small reduction in the concentration of resistin was detected (SI
Appendix, Fig. S2E). Measurement of blood-glucose concentra-
tion demonstrated that adipocyte IL6 deficiency partially sup-
pressed HFD-induced hyperglycemia in overnight fasted mice
(Fig. 2C), and this was associated with modestly improved tol-
erance to glucose (Fig. 2D). No changes in insulin tolerance were
detected in the HFD-fed mice (Fig. 2E and SI Appendix, Fig.
S2I), but we did detect slightly improved glucose-induced insulin
release in HFD-fed IL6-deficient mice compared with control
mice (Fig. 2F). Biochemical analysis of insulin signaling in
ADΔIL6 mice demonstrated that HFD-induced suppression of
insulin-stimulated phosphorylation of AKT on the activating
sites pSer473 and pThr308 was reduced in gWAT, but not in liver or
gastrocnemius muscle, compared with control ADWT mice (Fig. 2
G–I). Nevertheless, hyperinsulinemic–euglycemic clamp assays
demonstrated no significant differences between control and adi-
pocyte IL6-deficient mice (SI Appendix, Fig. S3A). Together, these
data demonstrate that adipocyte IL6 deficiency caused only modest
changes in the development of metabolic syndrome caused by the
consumption of a HFD (23).
Fig. 1. The HFD induced infiltration of macrophages and secretion of cyto-
kines. (A and B) The SVF of gWAT was isolated from HFD-fed (0, 4, and 16 wk)
mice and examined by flow cytometry to detect the total number of F4/80+
ATMs, the number of F4/80+ CD11c+ CD206− (M1-like) ATMs, and the number
of F4/80+ CD11c− CD206+ (M2-like) ATMs per mouse (mean ± SEM; n = 2). *P <
0.05; **P < 0.01; ***P < 0.001. (C) Total RNA was isolated from ADF and SVF
from HFD-fed (0, 4, and 16 wk) mice. The relative expression of mRNA asso-
ciated with makers of macrophages (Adgre1), M1-polarized macrophages
(Ccl2, Ccl5, Il6, and Tnfα), and adipocytes (Adipoq) was measured by qRT-PCR
assays (mean ± SEM; n = 4 ∼ 6). *P < 0.05; **P < 0.01; ***P < 0.001. (D) Total
RNAwas isolated from gWAT and BAT from CD- and HFD-fed ADWT and ADΔIL6
mice. The relative expression of Il6 mRNA was measured by qRT-PCR assays
(mean ± SEM; n = 5 ∼ 8). *P < 0.05; **P < 0.01. (E) Total RNAwas isolated from
gWAT and BAT in CD- and HFD-fed VWT and VΔIL6 mice. The relative expres-
sion of Il6 mRNA was measured by qRT-PCR assays (mean ± SEM; n = 4 ∼ 8).
*P < 0.05; ***P < 0.001.
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We found that adipocyte IL6 deficiency reduced the number
of F4/80+ crown-like structures in sections prepared from gWAT
of HFD-fed mice (Fig. 3A). Immunophenotyping analysis by flow
cytometry demonstrated that the consumption of a HFD increased
the number of ATMs in control mice and that this was suppressed
by adipocyte IL6 deficiency (Fig. 3B and SI Appendix, Fig. S3B).
The reduced immune-cell population included loss of both M1- and
M2-like macrophages (Fig. 3 B and C and SI Appendix, Fig. S3B)
together with reduced eosinophils and T cells (Fig. 3 D and E) and
was associated with reduced HFD-induced expression of chemokine
receptors CCR2 (and ligands CCL2, CCL7, and CCL8) and CCR5
(and ligands CCL3, CCL4, CCL5, and CCL8) (Fig. 3F).
Together, these data demonstrate that adipocyte IL6 in HFD-
fed mice promotes adipose tissue inflammation by increasing the
accumulation of ATMs in adipose tissue (Fig. 3) without causing
major changes in glycemia and insulin resistance (Fig. 2). This
conclusion is consistent with previous studies that have demon-
strated a role for IL6 in ATM accumulation that does not mark-
edly impact insulin resistance (21, 26).
Myeloid-Cell IL6 Suppresses HFD-Induced Adipose Tissue Inflammation.
To examine the role of IL6 secreted by myeloid cells, we compared
control VWT (Lyz2-Cre+/−) mice and mice with IL6 deficiency
(VΔIL6) in myeloid cells (Lyz2-Cre+/− Il6LoxP/LoxP). Metabolic
cage analysis of CD-fed mice demonstrated no significant dif-
ferences between VWT and VΔIL6 mice (SI Appendix, Fig. S4).
In contrast, IL6 deficiency in myeloid cells caused a significant
reduction in energy expenditure, but no significant change in
food consumption, when the mice were fed a HFD (Fig. 4). This
reduction in energy expenditure caused by myeloid cell IL6 de-
ficiency was associated with increased HFD-induced obesity (Fig. 5
A and B). These observations are consistent with prior studies that
identify a role for circulating IL6 in HFD-fed mice to promote
energy expenditure mediated by the paraventrical nucleus of the
hypothalamus (13).
We found that myeloid-cell IL6 deficiency was associated with
increased hyperglycemia (Fig. 5C) and hyperinsulinemia (SI Ap-
pendix, Fig. S5A), but changes in the circulating concentration of
the adipokines leptin or resistin were not detected (SI Appendix,
Fig. S5A). Moreover, the HFD-fed IL6-deficient mice were found
to be more glucose intolerant (Fig. 5D) and more insulin intolerant
(Fig. 5E and SI Appendix, Fig. S5B) than control HFD-fed mice,
but no significant changes in glucose-stimulated insulin secretion
were detected (Fig. 5F). Hyperinsulinemic–euglycemic clamp
studies confirmed that the HFD-fed myeloid-cell IL6-deficient
mice exhibited increased insulin resistance, as monitored by
reduced glucose infusion rate and whole-body glucose uptake,
compared with HFD-fed control mice (Fig. 5G). This increased
insulin resistance was associated with reduced suppression of en-
dogenous glucose production (EGP), reduced suppression of the
circulating concentration of nonesterified fatty acids (NEFAs),
increased whole-body turnover of both glycerol and palmitate, and
reduced glucose uptake by muscle and adipose tissue (Fig. 5G).
Biochemical analysis of the AKT signaling pathway in adipose
tissue, liver, and muscle demonstrated similar insulin-stimulated
phosphorylation of AKT on the activating sites pThr308 and pSer473 in
Fig. 2. Adipocyte IL6 promotes obesity-induced insulin resistance. (A) The change in body mass of CD- and HFD-fed ADWT and ADΔIL6 mice is presented
(mean ± SEM; n = 7 ∼ 14). (B) Body composition was examined by proton magnetic resonance spectroscopy (mean ± SEM; n = 7 ∼ 8). (C) The blood con-
centration of glucose in overnight fasted mice and the blood glucose concentration in fed mice were measured (mean ± SEM; n = 7 ∼ 14). **P < 0.01. (D) The
CD- and HFD-fed (16 wk.) mice were examined by GTTs (mean ± SEM; n = 7 ∼ 14). *P < 0.05; **P < 0.01. (E) The CD- and HFD-fed (16 wk) mice were examined
by ITTs (mean ± SEM; n = 5 ∼ 13). *P < 0.05; **P < 0.01. (F) GIR measurements were performed by i.p. injection of glucose (mean ± SEM; n = 6 ∼ 7). *P < 0.05.
(G–I) The CD- and HFD-fed mice (16 wk) were fasted overnight, treated by i.p. injection with 1 U/kg insulin (15 min), and examined by immunoblot analysis of
gWAT, liver, and gastrocnemius muscle by probing with antibodies to phospho-Akt (pThr308 and pSer473), Akt, and αTubulin. Relative quantitation of the
phospho-Akt immunoblots is presented below each subpanel.
Han et al. PNAS | February 11, 2020 | vol. 117 | no. 6 | 2753
IM
M
U
N
O
LO
G
Y
A
N
D
IN
FL
A
M
M
A
TI
O
N
IN
A
U
G
U
RA
L
A
RT
IC
LE
D
ow
nl
oa
de
d 
at
 U
NI
VE
RS
IT
Y 
O
F 
M
AS
SA
CH
US
ET
TS
 o
n 
M
ar
ch
 4
, 2
02
0 
CD-fed control and IL6-deficient mice, but reduced insulin-
stimulated AKT activation in HFD-fed IL6-deficient mice com-
pared with HFD-fed control mice (SI Appendix, Fig. S5 C–E).
These observations are consistent with increased hepatic steatosis
and serum lipoproteins in the HFD-fed IL6-deficient mice com-
pared with HFD-fed control mice (SI Appendix, Fig. S5 F–H).
Collectively, these data demonstrate that myeloid-cell IL6 de-
ficiency promotes increased insulin resistance in HFD-fed mice.
The increased HFD-induced insulin resistance of myeloid-cell
IL6-deficient mice (Fig. 5) may be related to increased adipose
tissue inflammation. Indeed, we found that myeloid-cell IL6 de-
ficiency caused increased numbers of F4/80+ crown-like structures
in sections prepared from the gWAT of HFD-fed mice (Fig. 6A).
Immunophenotyping analysis by flow cytometry demonstrated that
HFD consumption by control mice increased the number of
ATMs and that this increase was further promoted by myeloid-cell
IL6 deficiency (Fig. 6B and SI Appendix, Fig. S6). The increased
inflammatory cell population included increased numbers of
M1-like F4/80+ CD11c+ CD206− ATM macrophages, but not
M2-like F4/80+ CD11c− CD206+ ATM (Fig. 6 B and C), together
with increased eosinophils, neutrophils, and T cells (Fig. 6 D and E)
and was associated with increased expression of chemokine receptors
CCR2 (and ligands CCL2, CCL7, and CCL8) and CCR5 (and
ligands CCL3, CCL4, CCL5, and CCL8) (Fig. 6F).
Together, these data demonstrate that myeloid-cell IL6 in
HFD-fed mice improves glycemia and insulin resistance (Fig. 5)
and suppresses adipose tissue inflammation by reducing M1-like
macrophage polarization and ATM accumulation in adipose
tissue (Fig. 6).
IL6 Signaling Differentially Regulates Adipose Tissue Inflammation.
Our studies of macrophage and adipocyte IL6 deficiency lead to
opposite conclusions concerning the role of IL6 in adipose tissue
inflammation and metabolic syndrome. We show that adipocyte
IL6 is required for ATM accumulation, but causes only modest
changes in insulin resistance. In contrast, myeloid-cell IL6 suppresses
ATM accumulation and protects against the development of insulin
resistance. It is difficult to rationalize these two different actions of
IL6 within a single conceptual framework. To gain some insight into
this biological complexity, we examined an alternative physiologi-
cal mechanism that promotes IL6 signaling in adipose tissue. For
example, it is established that IL6 secreted by skeletal muscle after
exercise targets adipose tissue (11). We therefore compared adi-
pose tissue in control MWT mice (Mck-Cre+/−) and MΔIL6 mice
Fig. 3. Adipocyte IL6 promotes M1 polarization and an infiltration of ATMs. (A) ADWT and ADΔIL6 mice were fed a CD or a HFD for 16 wk. (A, Left) Sections of
gWAT were stained with hematoxylin and eosin. (Scale bar, 100 μm.) (A, Center) Macrophages were stained by using an antibody to F4/80 (green), and nuclei were
stained by using DAPI (blue) detection by fluorescencemicroscopy. (Scale bar, 50 μm.) (A, Right) ATMs were quantitated bymeasurement of F4/80 staining of tissue
section using ImageJ software (mean ± SEM; n = 9 ∼ 15). **P < 0.01. (B) The SVF of gWAT was isolated from CD- and HFD-fed (16 wk) mice and examined by flow
cytometry to detect the total number of ATMs (F4/80+), the number of M1-like ATMs (F4/80+ CD11c+ CD206−), and the number of M2-like ATMs (F4/80+ CD11c−
CD206+) (mean± SEM; n = 4). *P < 0.05; **P < 0.01. (C) Total RNAwas isolated from gWAT from CD- and HFD-fed ADWT and ADΔIL6 mice. The relative expression of
mRNA associated with markers of macrophages (Adgre1 and Cd68), M1-like polarized macrophages (Ccl2, Cd11c, and Tnfα), and M2-like polarized macrophages
(Arg1,Mgl1,Mgl2,Mrc1, andMrc2) was measured by qRT-PCR assays (mean ± SEM; n = 6 ∼ 8). *P < 0.05; **P < 0.01. (D and E) Total RNA was isolated from gWAT
from CD- and HFD-fed ADWT and ADΔIL6 mice. The relative expression of the eosinophil marker (Ccr3) and T cell markers (Cd4, Cd8, and Foxp3) were measured by
qRT-PCR assays of mRNA (mean ± SEM; n = 6 ∼ 8). *P < 0.05. (F) The relative expression of the receptor Ccr2 and the ligands Ccl2, Ccl7, and Ccl8; and the receptor
Ccr5 and the ligands Ccl3, Ccl4, Ccl5, and Ccl8 was measured by qRT-PCR assays of mRNA (mean ± SEM; n = 6 ∼ 8). *P < 0.05; **P < 0.01.
2754 | www.pnas.org/cgi/doi/10.1073/pnas.1920004117 Han et al.
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with skeletal muscle deficiency of IL6 (Mck-Cre+/− Il6LoxP/LoxP)
(SI Appendix, Fig. S7 A and B).
Examination of control and muscle IL6-deficient mice fed a
CD or a HFD demonstrated similar body mass; similar blood
concentrations of glucose, insulin, leptin, and resistin; and sim-
ilar tolerance to glucose and insulin (SI Appendix, Fig. S7 C–H).
Muscle IL6 therefore appeared to play no obvious metabolic
role. However, the increased blood concentration of IL6 ob-
served in control mice after exercise was reduced in muscle IL6-
deficient mice (Fig. 7A). This suppression of circulating IL6 did
not cause significant (P < 0.05) changes in tolerance to glucose
or insulin (Fig. 7 B and C). However, the accumulation of ATMs
(primarily M1-like macrophages) by gWAT was increased in the
muscle IL6-deficient mice compared with control mice (Fig. 7D)
and was associated with increased expression of chemokine re-
ceptors CCR2 (and ligands CCL2, CCL7, and CCL8) and CCR5
(and ligands CCL3, CCL4, CCL5, and CCL8) (Fig. 7E). These
data indicate that muscle IL6 functions to suppress adipose tis-
sue inflammation by decreasing the accumulation of ATMs.
Adipose Tissue Inflammation Is Determined by the Source of IL6
Expression. Our analysis demonstrates that IL6 expression by ad-
ipocytes promotes the accumulation of ATMs (Fig. 3), while IL6
expression by myeloid cells and muscle suppresses ATM accumu-
lation (Figs. 6 and 7). To identify mechanisms that might con-
tribute to this difference in IL6 signaling, we profiled gWAT gene
expression for differences between IL6 deficiency in adipocytes,
myeloid cells, and muscle. This analysis demonstrated increased
expression of the metalloproteases ADAM10 and ADAM17 by
gWAT in mice with IL6 deficiency in muscle or myeloid cells that
was not detected in gWAT from mice with adipocyte deficiency of
IL6 (Fig. 7F). The increased expression of Adam10 and Adam17
was associated with increased expression of the IL6 receptor (Il6rα
and Il6st) and increased expression of the IL6 target gene Socs3
(Fig. 7F). Interestingly, ADAM10 and ADAM17 control the for-
mation of soluble IL6-Rα and, thus, the switch of IL6 signaling
from a canonical mode to a noncanonical trans-signaling mode (5).
This switch in IL6 signaling may contribute to the different phe-
notypes detected in mice with IL6 deficiency in adipocytes com-
pared with myeloid cells and muscle (5). Indeed, it is established
that while canonical IL6 signaling suppresses ATM accumulation
(6), IL6 trans-signaling promotes ATM accumulation (26).
Discussion
Recent studies have provided significant insight into the meta-
bolic actions of IL6, a potent cytokine that is secreted by several
Fig. 4. Myeloid-cell IL6 increases energy expenditure. Metabolic cage analysis of CD- and HFD-fed VWT and VΔIL6 mice (6 wk) to measure oxygen consumption
(VO2), carbon dioxide production (VCO2), respiratory exchange rate (RER), energy expenditure (EE), and activity (A and B) and food intake per mouse (C) is
presented (mean ± SEM; n = 8). **P < 0.01; ***P < 0.001.
Han et al. PNAS | February 11, 2020 | vol. 117 | no. 6 | 2755
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tissues (1). However, little is known about the source of IL6
expression under different physiological conditions. Neverthe-
less, it is established that exercise causes increased IL6 expres-
sion by muscle (27), insulin signaling on AgRP neurons in the
hypothalamus causes increased hepatic expression of IL6 (28),
and obesity increases IL6 expression by adipose tissue (24, 25).
Previous studies have demonstrated that the source of IL6
may influence the consequence of IL6 signaling. Thus, hepatic
IL6 signaling is different when IL6 is secreted by resident
Kupffer cells or adipose tissue depots (10, 29). Adipocyte-
derived IL6 causes decreased hepatic expression of the adapter
protein IRS1 (10). In contrast, Kupffer cell-derived IL6 pro-
motes expression of the adapter protein IRS2 by hepatocytes
(29). This difference in the signaling response to different physio-
logical sources of IL6 represents one aspect of the complexity of
IL6 function.
The purpose of this study was to examine IL6 expression by
adipose tissue during the response to obesity. We tested the role
of IL6 expression by adipocytes or myeloid cells by comparing
mice with selective Il6 gene ablation. We found that adipocyte
IL6 knockout mice manifested decreased ATM accumulation,
increased energy expenditure, and relatively minor differences in
whole-body glucose homeostasis when fed a HFD (Figs. 2 and 3).
In contrast, HFD-fed myeloid cell IL6 knockout mice manifested
decreased energy expenditure, which predisposed them to in-
creased body weight, increased hepatic steatosis, and insulin
resistance (Figs. 5 and 6), and HFD-fed muscle IL6 knockout
mice manifested increased ATM accumulation following exercise
(Fig. 7). These data demonstrate that the physiological meta-
bolic response to IL6 depends on the specific source of IL6
in vivo, where adipocyte-derived IL6 promotes ATM accumu-
lation in the absence of major changes in glucose or insulin
tolerance, whereas myeloid cell-derived IL6 suppresses M1-like
macrophage polarization and ATM accumulation and improves
glucose and insulin tolerance, and exercise-induced muscle IL6
suppresses ATM accumulation.
Canonical IL6 signaling involves binding of IL6 to an IL6-Rα/
IL6ST complex at the plasma membrane that activates the JAK1–
STAT3 pathway (5). Targets of this signaling pathway include the
IL4-Rα on macrophages that that promotes alternative (M2a)
activation and suppression of obesity-induced insulin resistance
(6). It is likely that a defect in this mechanism contributes to the
Fig. 5. Macrophage IL6 suppresses diet-induced insulin resistance. (A) The change in body mass of CD- and HFD-fed VWT and VΔIL6 mice is presented
(mean ± SEM; n = 6 ∼ 8). *P < 0.05; **P < 0.01; ***P < 0.001. (B) Body composition was examined by proton magnetic resonance spectroscopy (mean ±
SEM; n = 6 ∼ 8). *P < 0.05; **P < 0.01. (C) The blood concentration of glucose in overnight fasted mice and fed mice was measured (mean ± SEM; n = 6 ∼ 8).
**P < 0.01. (D) CD- and HFD-fed (16 wk) mice were examined by GTTs (mean ± SEM; n = 5 ∼ 8). *P < 0.05; **P < 0.01). (E ) CD- and HFD-fed (16 wk) mice
were examined by ITTs (mean ± SEM; n = 5 ∼ 8). *P < 0.05; **P < 0.01. (F ) CD- and HFD-fed (16 wk) mice were examined by GIR (mean ± SEM; n = 5 ∼ 7).
(G) Hyperinsulinemic–euglycemic clamps of CD- and HFD-fed (8 wk) mice were used to measure the glucose infusion rate, whole-body glucose uptake,
EGP, NEFA suppression, whole-body glycerol turnover, whole-body palmitate turnover, and glucose uptake in gWAT, subcutaneous WAT (scWAT), and
gastrocnemius muscle (mean ± SEM; n = 3 ∼ 6). *P < 0.05; **P < 0.01.
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inflammatory phenotype (increased ATMs, increased M1-like
macrophages, and insulin resistance) of mice with IL6 deficiency
in myeloid cells (Figs. 4–6).
Noncanonical (trans) IL6 signaling is mediated by the interac-
tion of IL6ST with a proteolytically processed (soluble) form of
IL6-Rα bound to IL6 (5). The formation of soluble IL6-Rα is
largely mediated by the metalloproteases ADAM10 and ADAM17
(5). It is established that trans-signaling by IL6 potently promotes
ATM recruitment (26). This trans-signaling mechanism most likely
accounts for the effect of adipocyte IL6 to increase ATM re-
cruitment (Fig. 6) because of increased ADAM10 and ADAM17
expression (Fig. 7F).
An intriguing aspect of trans signaling is that the promoted
ATM recruitment does not cause major changes in insulin re-
sistance (26), including in mice with adipocyte IL6 deficiency
(Fig. 2). This is in contrast to canonical IL6 signaling that reg-
ulates insulin sensitivity (6), including in mice with myeloid-cell
IL6 deficiency (Fig. 5). This difference in the insulin-resistance
response to IL6 may relate to the direct actions of canonical IL6
signaling to promote anti-inflammatory M2a macrophage po-
larization (6) that have not been reported for noncanonical IL6
signaling (26). The mechanism that accounts for this difference
in IL6 signaling is unclear. However, it is possible that autocrine
IL6 signaling by myeloid cells triggers canonical signaling, while
paracrine/endocrine signaling by adipocytes and muscle leads to
noncanonical signaling.
In conclusion, this study has identified a layer of complexity in
the physiology of the metabolic actions of IL6 by showing that
the source of cytokine expression can determine the inflamma-
tory signaling response. Thus, the physiological context of IL6
signaling is important for IL6 function. For example, muscle can
secrete IL6 following exercise (27) and suppress ATM accumu-
lation in adipose tissue. In contrast, adipocytes can secrete IL6
in response to obesity (1) and increase ATM accumulation. This
mechanistic plasticity enables IL6 to promote an appropriate
biological response within a specific physiological context.
Materials and Methods
Animals. C57BL/6J mice (stock no. 000664), B6.129P2-Lyz2tm1(cre)Ifo/J mice (stock
no. 004781) (30), and B6;FVB-Tg(Adipoq-Cre)1Evdr mice (stock no. 028020)
(31) were obtained from The Jackson Laboratory. The Il6LoxP/LoxP mice have
been described (32). Mice were back-crossed to the C57BL/6J strain (10 gen-
erations) and housed in a specific pathogen-free facility accredited by the
American Association for Laboratory Animal Care using laminar flow cages.
Male mice (age 8 wk.) were fed a CD or a HFD (33). The studies were ap-
proved by the Animal Care and Use Committees of the University of Mas-
sachusetts Medical School and Yale University Medical School.
Fig. 6. Macrophage IL6 suppresses the accumulation and M1-like polarization of ATMs. (A, Left) CD- and HFD-fed (16 wk)VWT andVΔIL6 mice were examined
by staining sections of gWAT with hematoxylin and eosin. (Scale bar, 100 μm.) (A, Center) Macrophages were stained by using an antibody to F4/80 and
detection by fluorescence microscopy. (Scale bar, 50 μm.) (A, Right) ATMs were quantitated by measurement of F4/80 staining of tissue sections using ImageJ
software (mean ± SEM; n = 8 ∼ 11). ***P < 0.001. (B) The SVF of gWAT was isolated from VWT and VΔIL6 CD- and HFD-fed (16 wk) mice and examined by flow
cytometry to detect the total number of ATMs (F4/80+), M1-like ATMs (F4/80+ CD11c+ CD206−), andM2-like ATMs (F4/80+ CD11c− CD206+) (mean ± SEM; n = 5).
*P < 0.05. (C) Total RNA was isolated from gWAT of CD- and HFD-fed VWT and VΔIL6 mice (16 wk). The relative expression of mRNA associated with
macrophages (Adgre1 and Cd68), M1-like polarized macrophages (Ccl2, Cd11c, and Tnfα), and M2-like polarized macrophages (Arg1, Mgl1, Mgl2, Mrc1, and
Mrc2) was measured by qRT-PCR assays (mean ± SEM; n = 5 ∼ 8). *P < 0.05; **P < 0.01; ***P < 0.001. (D and E) The relative expression of the eosinophil marker
(Ccr3), neutrophil marker (Mpo), and T cell markers (Cd4, Cd8, and Foxp3) were measured by qRT-PCR assays of mRNA (mean ± SEM; n = 5 ∼ 8). *P < 0.05,
***P < 0.001. (F) The relative expression of the receptor Ccr2 (and ligands Ccl2, Ccl7, and Ccl8) and the receptor Ccr5 (and ligands Ccl3, Ccl4, Ccl5, and Ccl8)
were measured by qRT-PCR assays of mRNA (mean ± SEM; n = 5 ∼ 8). *P < 0.05; **P < 0.01.
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Exercise.Mice ran on a treadmill (Columbus Instrumentsmodel 1055-SRM-D58)
at 10 m/min at a 0° inclination (15 min) followed by a gradual increase to
18 m/min with a 5° inclination (60 min or until exhaustion). Mice were accli-
mated to the treadmill running (8 m/min for 15 min) every other day for 1 wk
before the test. Glucose tolerance tests (GTTs) (prefasted 5 h), insulin tolerance
tests (ITTs), and gene-expression studies were performed 1 h after exercise.
Genotype Analysis.Genomic DNAwas genotypedby using a PCR-basedmethod.
Cre+ (450 bp) was detected by using amplimers 5′-TTACTGACCGTACACCAAA-
TTTGCCTGC-3′ and 5′-CCTGGCAGCGATCGCTATTTTCCATGAGTG-3′. Il6LoxP (420 bp)
and Il6WT (317 bp) were detected by using amplimers 5′-CCCACCAAGAA-
CGATAGTCA-3′ and 5′-GGTATCCTCTGTGAAGTCCTC-3′. Il6Δ (260 bp), Il6LoxP
(1,000 bp), and Il6WT (900 bp) were detected by using amplimers
5′-CCCACCAAGAACGATAGTCA-3′ and 5′-ATGCCCAGCCTAATCTAGGT-3′.
RNA Analysis. These methods have been described (34). The expression of
mRNA was examined by qPCR analysis using a Quantstudio PCR machine
(Life Technologies). TaqMan assays were used to quantitate Adam10
(Mm00545742_m1), Adam17 (Mm00456428_m1), Adgre1 (Mm00802529_m1),
Adipoq (Mm00456425_m1), Arg1 (Mm00475988_m1), Ccl2 (Mm00441242_m1),
Ccl3 (Mm00441259_g1), Ccl4 (Mm0044311_m1), Ccl5 (Mm01302427_m1),
Ccl7 (Mm01308393_g1), Ccl8 (Mm01297183_m1), Ccr2 (Mm00438270_m1),
Ccr3 (Mm00515543_s1), Ccr5 (Mm01963251_s1), Cd11c (Mm00498698_m1),
Cd4 (Mm00442754_m1), Cd68 (Mm00839639_g1), Cd8a (Mm01182107_g1),
Foxp3 (Mm00475162_m1), Il6 (Mm00446190_m1), Il6rα(Mm00439653_m1),
Il6st (Mm00439665_m1), Mgl1 (Mm00546125_g1), Mgl2 (Mm00460844_m1),
Mpo (Mm01298424_m1), Mrc1 (Mm00485148_m1), Mrc2 (Mm00485184_m1),
Socs3 (Mm00545913_s1), and Tnfα (Mm00443258_m1). The relative mRNA
expression was normalized by measurement of the amount of 18S RNA in each
sample using Taqman© assays (catalog no. 4352339E, Life Technologies).
Immunoblot Analysis. These methods have been described (34). Intraperitoneal
(i.p.) injection of mice with saline (control) or 1 U/kg insulin (15 min) was
performed. Tissue extracts were prepared by using Triton Lysis Buffer
Fig. 7. Muscle IL6 suppresses the accumulation and M1-like polarization of ATMs. (A) The concentration of circulating IL6 in blood was measured from exercised CD-
or HFD-fed (16 wk) MWT and MΔIL6 mice (mean ± SEM; n = 6). *P < 0.05. The exercise (EX) time is presented. (B) The exercised CD- and HFD-fed (16 wk) mice were
examined by GTTs (mean ± SEM; n = 6). (C) The exercised CD- and HFD-fed (16 wk.) mice were examined by ITTs (mean ± SEM; n = 6). (D) Total RNAwas isolated from
gWAT from CD- and HFD-fed MWT and MΔIL6 mice (16 wk). The relative expression of mRNA associated with macrophages (Adgre1 and Cd68), M1-like polarized
macrophages (Ccl2, Cd11c, and Tnfα), andM2-like polarizedmacrophages (Arg1,Mgl1,Mgl2,Mrc1, andMrc2) weremeasured by qRT-PCR assays (mean± SEM; n= 5∼
7). *P < 0.05; **P < 0.01; ***P < 0.001. (E) The relative expression of the receptor Ccr2 (and ligands Ccl2, Ccl7, and Ccl8) and the receptor Ccr5 (and ligands Ccl3, Ccl4,
Ccl5, and Ccl8) were measured by qRT-PCR assays of mRNA (mean ± SEM; n = 5 ∼ 7). *P < 0.05; **P < 0.01. (F) The relative expression of IL6 pathway-associated genes
(Socs3, Il6st, Il6rα, Adam10, and Adam17) by gWAT was measured by qRT-PCR assays of mRNA (mean ± SEM; n = 5 ∼ 8). *P < 0.05; **P < 0.01.
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(20 mM Tris [pH 7.4], 1% Triton X-100, 10% glycerol, 137 mM NaCl, 2 mM
ethylenediaminetetraacetic acid, 25 mM β-glycerophosphate, 1 mM sodium
orthovanadate, 1 mM phenylmethylsulfonyl fluoride, and 10 μg/mL aprotinin
plus leupeptin). Extracts (20 to 50 μg of protein) were examined by protein
immunoblot analysis by probing with antibodies to AKT (catalog no. 9272;
Cell Signaling Technology), pSer473 AKT (catalog no. 9271; Cell Signaling
Technology), pThr308 AKT (catalog no. 4056; Cell Signaling Technology), and
αTubulin (clone B-5-1-2; catalog no. T5168; Millipore Sigma). IRDye 680LT
conjugated-donkey anti-mouse IgG antibody (catalog no. 926-68022; LI-COR
Biosciences) and IRDye 800CW conjugated-goat anti-rabbit IgG (catalog no.
926-32211; LI-COR Biosciences) were used to detect and quantitate immune
complexes with the Odyssey infrared imaging system (LI-COR Biosciences).
Measurement of Blood Glucose and Adipokine Concentration. These methods
have been described (34, 35). Blood glucose was measured with an Ascensia
Breeze 2 glucometer (Bayer). Insulin, leptin, IL6, and resistin in plasma were
measured by enzyme-linked immunosorbent assay using a Luminex 200
machine (Millipore).
GTTs and ITTs.GTTs and ITTs were performed by using describedmethods (10).
Glucose-Induced Insulin Release. Glucose-induced insulin release (GIR) mea-
surements were performed by i.p. injection of glucose (2 g/kg) and mea-
surement of blood insulin concentration at 0, 5, and 15 min.
Lipid Analysis. Hepatic triglyceride was measured by using a kit purchased
from Sigma (catalog no. TR0100). Blood lipoprotein analysis was performed
by the University of Cincinnati Mouse Metabolic Phenotyping Center.
Body Temperature. Biocompatible and sterile microchip transponders (IPTT-300
Extended Accuracy Calibration; Bio Medic Data Systems) were implanted, and
core body temperature was measured by telemetry.
Hyperinsulinemic-Euglycemic Clamp Studies. Basal infusion and hyperinsulinemic–
euglycemic clamp studies were performed after an overnight fast to assess
whole-body and hepatic insulin sensitivity (9).
Metabolic Cages. The analysis was performed by the Mouse Metabolic Phe-
notyping Center at the University of Cincinnati (35). The mice were housed
under controlled temperature and lighting with free accesses to food and
water. Respiratory exchange ratio and energy exchange ratio were mea-
sured by using metabolic cages.
Analysis of Tissue Sections. Themethods used for the analysis of tissue sections
have been described (34, 35). Histology was performed by using tissue fixed
in 10% formalin for 24 h, dehydrated, and embedded in paraffin. Sections
(7 μm) were cut and stained by using hematoxylin and eosin (AmericanMaster
Tech Scientific). Immunohistochemistry was performed by using deparaffi-
nized tissue sections that were incubated in blocking buffer for 1 h (1% bo-
vine serum albumin [BSA] and 10% normal goat serum in phosphate-buffered
saline [PBS]) and permeabilized with 0.1% Triton X-100. The sections were
incubated in blocking buffer containing the primary antibody F4/80 (catalog
no. ab6640; Abcam). The primary antibody was detected by incubation with
goat-anti rabbit IgG-Alexa Fluor 488 (catalog no. A2704; ThermoFisher Scien-
tific). DNA was detected by staining with DAPI (catalog no. D3571; Invitrogen).
Fluorescence was visualized by using a Leica TCS SP2 confocal microscope
equipped with a 405-nm diode laser.
Adipocyte and Stromal Vascular Cell Isolation. The SVF of gonadal white fat
(gWAT) was isolated (36). Briefly, gWAT was excised and minced into 10 mL
of KRB solution (12.5 mM Hepes [pH 7.4], 120 mM NaCl, 6 mM KCl, 1.2 mM
MgSO4, 1 mM CaCl2, 2% BSA, and 2.5 mM glucose). Collagenase II (catalog
no. C6885; Sigma; 1 mg/mL) and DNase I (catalog no. DN-25; Sigma; 0.2 mg/mL)
were added, and the tissue was incubated at 37 °C with shaking (40 min).
Larger particles were removed by using a 100-μm nylon sieve, and the filtrates
were centrifuged at 1,000 rpm (3 min). Floating adipocytes were washed twice
with PBS prior to RNA isolation. Nonadipocyte layers were collected, centri-
fuged at 3,000 rpm (5 min), and washed with PBS supplemented with 2% fetal
bovine serum (FBS). The cells were treated (10 min) with 500 μL of Ack lysis
buffer (catalog no. A10492; ThermoFisher Scientific) and washed prior to RNA
isolation and flow cytometry.
Flow Cytometry. Cell-surface antigens were examined by using cells stained
with the Invitrogen LIVE/DEAD Fixable Blue Dead Cell Stain Kit (catalog no.
L23105; ThermoFisher Scientific), 2% FBS–PBS plus FcBlock (catalog no. 553142;
BD Bioscience), and conjugated antibodies including F4/80-Phycoerythrin
(catalog no. 123110; Biolegend), CD206-Alexa Fluor 488 (catalog no.
MCA2235A488; AbD serotec), and CD11c-Alexa Fluor 700 (catalog no.
56-0114-82; eBioscience) (33). Isotype control antibodies for Cd11c (Alexa
Fluor 700 isotype control. catalog no. 56-4888-80) and CD206 (Alex Fluor
488 isotype control; catalog no. 400233) were obtained from ThermoFisher
Scientific. The cells were washed and subsequently fixed with 2% para-
formaldehyde. Analysis was performed by using a LSR-II cytometer (Becton
Dickenson). Data were processed by using FlowJo Software (Tree Star).
Statistical Analysis. Data are presented as the mean and SE. Statistical analysis
was performed by using GraphPad Prism (Version 7; GraphPad Software).
ANOVA with Bonferroni’s test was used to determine significance with an
assumed CI of 95%. Two-tailed, unpaired t test with Welch’s correction was
used for pairwise comparisons. Statistical significance was defined as P < 0.05.
Material and Data Availability. Sources for materials used in this study are
described in Materials and Methods. The raw data obtained for this study
are presented in Datasets S1 and S2.
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